Informatie:
Fout:
Trefwoorden
Onkologie, medizinische ×
- Clinical Trial (17)
- Adverse event (17)
- Concomitant Medication (4)
- Gynecology (4)
- Ovarian Neoplasms (4)
- Uterine Cervical Neoplasms (3)
- Small Cell Lung Carcinoma (3)
- Lung Neoplasms (3)
- Rectal Neoplasms (2)
- Vomiting (2)
- Pulmonary Medicine (2)
- Topotecan (2)
- Non Small Cell Lung Cancer (2)
- Nausea (2)
- Peritoneal Neoplasms (1)
- Pharmacokinetics (1)
- Drugs, Investigational (1)
- Lymphoma, B-Cell (1)
- Chemotherapy, Adjuvant (1)
- Biopsy (1)
- Chemoradiotherapy (1)
- Diagnostic Imaging (1)
- Disease (1)
- Alcohol Drinking (1)
- Fallopian Tube Neoplasms (1)
- Laboratories (1)
- Liver (1)
Inhoudsopgave
Geselecteerde datamodellen
U moet ingelogd zijn om meerdere datamodellen te selecteren en die te downloaden of te analyseren.
17 Zoekresultaten.
Itemgroepen: Administrative, Laboratory Reference Ranges, Laboratory Reference Ranges , Concomitant Medication - Continued, Adverse Experiences (Non-serious), Adverse Experiences (Non-serious), Investigator's Signature (Adverse Experience)
Itemgroepen: Administrative, Serious Adverse Experience (SAE), Serious Adverse Experience - Relevant Laboratory Data
Itemgroepen: Administrative, Concomitant Medication, Adverse Experiences (Non-serious), Adverse Experiences (Non-serious), Investigator's Signature (Adverse Experience), Course Conclusion, Investigator's Signature (Study Conclusion)
Itemgroepen: Administrative, Serious Adverse Event, Serious Adverse Event (SAE) - Section 1, Serious Adverse Event (SAE) - Section 2 (Seriousness), Serious Adverse Event (SAE) - Section 3 (Demography Data), Serious Adverse Event (SAE) - Section 4 (If Investigational Product(s) was Stopped, Did the Reported Event(s) Recur After Further Investigational Product(s) were Administered?), Serious Adverse Event (SAE) - Section 5 (Possible Causes of SAE Other Than Investigational Product(s)), Serious Adverse Event (SAE) - Section 6 (Relevant Medical Conditions), Serious Adverse Event (SAE) - Section 7 (Other relevant Risk Factors) , Serious Adverse Event (SAE) - Section 8 (Relevant Concomitant Medications) , Serious Adverse Event (SAE) - Section 9 (Details of Investigational Product(s)), Was treatment blind broken at investigational site?, Serious Adverse Event (SAE) - Section 10 (Details of relevant Assessments), Serious Adverse Event (SAE) - Section 11 (Narrative Remarks) , Investigator’s signature, Serious Adverse Event (SAE) - Additional/ Follow-Up Information
Itemgroepen: Administrative, Any Adverse Events?, Non-serious Adverse Event
Itemgroepen: Non-Serious Adverse Event, Serious Adverse Event, SAE - Type of Report, SAE- Randomisation, SAE - Seriousness, SAE - Relevant Concomitant Medications, SAE - Relevant Medical Conditions/ Risk Factors, SAE - Relevant Diagnostic Results, SAE - Rechallenge, SAE - Investigational Product, SAE - Investigational Product, SAE - Investigational Product , SAE - General Narrative Comments, SAE - Non clinical, Concomitant Medications
Itemgroepen: Administrative, Are there any non-serious adverse events to report?, Non-Serious adverse Events, Serious Adverse Event #1, Serious Adverse Event #1 - Relevant Laboratory Data, Serious Adverse Event #1 - Signature, Prior and Concomitant Medications, Prior and Concomitant Medications
Itemgroepen: Administrative documentation, Serious Adverse Event, Serious Adverse Event. Laboratory test finding, Serious Adverse Event, Comment, Serious Adverse Event, Randomization, Serious Adverse Event, Investigator Signature
Itemgroepen: Administrative documentation, Non-Serious Adverse Event
Itemgroepen: Administrative documentation, Adverse event
Itemgroepen: Liver Events, Investigational Product (Liver) , Alcohol intake, Medical Conditions (Liver), Drug related liver disease conditions, Other liver disease conditions, Other medical conditions, Pharmacokinetics (Liver PK), Liver Biopsy, Liver imaging
Itemgroepen: Administrative documentation, Serious Adverse Event, Serious Adverse Event, Seriousness of Adverse Event, Serious Adverse Event, Demography, Serious Adverse Event, Relationships, Experimental drug, Serious Adverse Event, Etiology aspects, Serious Adverse Event, Disease, Relevance, Serious Adverse Event, Risk factors, Serious Adverse Event, Concomitant Agent, Serious Adverse Event, Experimental drug, Serious Adverse Event, Evaluation, Serious Adverse Event, Comment, Serious Adverse Event, Investigator Signature